Trial Profile
Effects of Liraglutide on Epicardial Fat Pro-Inflammatory Genes in Type 2 Diabetes and Coronary Artery Disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 14 Mar 2024 Planned primary completion date changed from 31 Mar 2024 to 30 Jun 2024.
- 13 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Mar 2024.
- 31 Oct 2023 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.